ImmuPharma's Lupuzor succeeds in Phase II lupus trial
This article was originally published in Scrip
Executive Summary
ImmuPharmahas announced positive interim results of its Phase IIb study of its T-cell inhibitor Lupuzor (IPP-201101) for the treatment of systemic lupus erythematosus. The London-based company is preparing to progress the drug into Phase III development in the next six months.